Exelixis (EXEL) Return on Invested Capital (2011 - 2017)

Exelixis' (EXEL) quarterly Return on Invested Capital came in at 0.01% in Q4 2017, up 39.43% quarter-over-quarter from 0.01% in Q3 2017.

Exelixis (EXEL) Return on Invested Capital (2011 - 2017) Analysis & Trends

Exelixis' Return on Invested Capital history runs 5 years deep, the most recent figure standing at 0.01% for Q4 2017.

On a quarterly basis, Return on Invested Capital changed N/A year-over-year to 0.01% in Q4 2017; TTM through Dec 2017 was 0.01%, a N/A change from a year earlier, with the FY2014 full-year figure at 0.04%, up 16.0% from the prior year.
Return on Invested Capital improved to 0.01% in Q4 2017 per EXEL's latest filing, from 0.01% in the prior quarter.
Across five years, Return on Invested Capital topped out at 0.01% in Q4 2017 and bottomed at 0.09% in Q1 2016.
The 3-year median for Return on Invested Capital is 0.03% (2013), against an average of 0.03%.
Across the five-year window, Return on Invested Capital declined 5 bps in 2013 and rose 9 bps in 2017, its largest moves.
Year by year, Return on Invested Capital stood at 0.05% in 2013, then soared by 72 bps to 0.01% in 2016, then surged by 168 bps to 0.01% in 2017.
Per Business Quant, the three latest EXEL Return on Invested Capital figures stand at 0.01% (Q4 2017), 0.01% (Q3 2017), and 0.0% (Q2 2017).

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Exelixis	14.38 Bn	13.60 Bn	590.86 Mn	-

Download Data